Technical Analysis for ATHX - Athersys, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Historical ATHX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | 1.16% | |
| Hammer Candlestick | Bullish | 6.71% | |
| NR7 | Range Contraction | 6.71% | |
| MACD Bearish Signal Line Cross | Bearish | 7.36% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 3.55% | |
| Outside Day | Range Expansion | 3.55% | |
| NR7 | Range Contraction | 1.74% | |
| Inside Day | Range Contraction | 1.74% | |
| Down 3 Days in a Row | Weakness | 3.86% | |
| Down 4 Days in a Row | Weakness | 3.86% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 3% | about 4 hours ago |
| Up 2% | about 5 hours ago |
| 20 DMA Resistance | about 5 hours ago |
| Rose Above 20 DMA | about 6 hours ago |
| 60 Minute Opening Range Breakout | about 6 hours ago |
Get a Trading Assistant
- Earnings date: 05/05/2021
Athersys, Inc. Description
Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The company's lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase I clinical trials and is under two ongoing Phase II clinical trials for treating a range of diseases and various application in the field of clinical regenerative medicine. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing novel pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Diseases Clinical Development Pharmaceuticals Diabetes Pharmacy Bone Drug Discovery Clinical Trial Schizophrenia Cardiovascular Disease Inflammatory Bowel Disease Obesity Regenerative Medicine Immune Disorders Cell Product Mesoblast Orthopedic Applications Platform Product
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.39 |
| 52 Week Low | 1.53 |
| Average Volume | 2,746,215 |
| 200-Day Moving Average | 2.07 |
| 50-Day Moving Average | 1.98 |
| 20-Day Moving Average | 1.75 |
| 10-Day Moving Average | 1.73 |
| Average True Range | 0.12 |
| ADX | 22.04 |
| +DI | 17.37 |
| -DI | 22.64 |
| Chandelier Exit (Long, 3 ATRs ) | 1.62 |
| Chandelier Exit (Short, 3 ATRs ) | 1.92 |
| Upper Bollinger Band | 1.95 |
| Lower Bollinger Band | 1.55 |
| Percent B (%b) | 0.46 |
| BandWidth | 22.91 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.001 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.91 | ||||
| Resistance 3 (R3) | 1.89 | 1.82 | 1.88 | ||
| Resistance 2 (R2) | 1.82 | 1.77 | 1.83 | 1.87 | |
| Resistance 1 (R1) | 1.77 | 1.74 | 1.80 | 1.79 | 1.86 |
| Pivot Point | 1.70 | 1.70 | 1.71 | 1.71 | 1.70 |
| Support 1 (S1) | 1.65 | 1.65 | 1.68 | 1.67 | 1.60 |
| Support 2 (S2) | 1.58 | 1.62 | 1.59 | 1.59 | |
| Support 3 (S3) | 1.53 | 1.58 | 1.58 | ||
| Support 4 (S4) | 1.55 |
